Splenomegaly

1. Clinical Overview

Summary

Splenomegaly is the abnormal enlargement of the spleen, clinically defined as a palpable spleen (which usually indicates a size at least twice normal) or radiologically as a craniocaudal length greater than 12-13 cm on ultrasound or CT. It is a non-specific sign that serves as a "clinical barometer" for a vast array of systemic pathologies, ranging from benign infections to life-threatening malignancies.

The spleen's unique anatomical position in the portal circulation and its role as a reticuloendothelial filter make it susceptible to enlargement via three primary mechanisms: congestion (e.g., cirrhosis), infiltration (e.g., lymphoma, Gaucher's disease), and hyperplasia (e.g., hemolysis, chronic infection). While mild splenomegaly is often reactive and self-limiting (as in EBV), massive splenomegaly (extending into the pelvis or crossing the midline) is a specific indicator of myeloproliferative neoplasms (Myelofibrosis, CML), tropical diseases (Malaria, Leishmaniasis), or storage disorders.

Clinicians must distinguish the finding of an enlarged spleen from "hypersplenism," which refers to the functional consequence of pancytopenia. The diagnostic challenge involves navigating a broad differential diagnosis while identifying red flags for immediate intervention, such as splenic rupture or acute leukemic transformation. Management is strictly directed at the underlying cause, with splenectomy reserved for refractory cases, gross symptoms, or massive size, always balanced against the lifelong risk of Overwhelming Post-Splenectomy Infection (OPSI).

Key Facts

• Definition (Radiological): Spleen length > 12-13 cm (varies by height/sex).
• Definition (Clinical): ANY palpable spleen is pathological until proven otherwise (palpability usually implies > 1.5-2x enlargement).
• Normal Dimensions: Rule of 1-3-5-7-9-11 (1x3x5 inches, 7oz weight, lies between ribs 9-11).
• Massive Splenomegaly: Definition varies, typically > 20 cm length or > 1000g weight.
• Hypersplenism: The clinical triad of Splenomegaly + Cytopenia(s) + Normal/Hyperplastic Bone Marrow.
• Commonest Cause (Global): Malaria (hyperendemic regions) and Schistosomiasis.
• Commonest Cause (Western): Hematologic malignancy (Lymphoma > Leukemia) and Portal Hypertension (Cirrhosis).
• Accessory Spleens (Splenunculi): Present in 10-30% of population; can enlarge post-splenectomy causing recurrent ITP.
• Spontaneous Rupture: Rare catastrophe, associated with EBV (Infectious Mononucleosis), Malaria, and Acute Leukemia.
• Prognosis: Spleen size correlates with tumor burden in CML and Myelofibrosis; reduction is a key therapeutic endpoint.

Clinical Pearls

Diagnostic Pearl: A palpable spleen moves inferomedially towards the right iliac fossa on inspiration. Always start palpating in the RIF to avoid missing the lower edge of a massive spleen.

Differentiation Pearl: You cannot get above the spleen (unlike the kidney). The spleen has a medial notch, acts dull to percussion, and is not ballotable.

Castell's Sign: With the patient supine, percuss the lowest intercostal space in the left anterior axillary line. It should be resonant (gastric bubble). If it becomes dull on full inspiration, splenomegaly is PROBABLE (82% sensitivity).

Traube's Space: A crescent-shaped space bounded by the left lung, anterior border of the spleen, costal margin, and inferior margin of the left lobe of the liver. Dullness here implies splenomegaly (or a full stomach/pleural effusion).

Safety Pearl: In acute viral splenomegaly (e.g., Glandular Fever), contact sports are absolutely contraindicated for at least 3-4 weeks due to the high risk of rupture from minor trauma.

Why This Matters Clinically

Sentinel Sign: Splenomegaly is often the only physical sign of an underlying occult malignancy (Early Lymphoma/CML) or chronic liver disease (compensated cirrhosis). Identifying it shifts the diagnostic paradigm immediately.

Haematological Crisis: In acute leukemia or blast crisis, rapid splenic enlargement can cause capsular pain (capsulitis) and infarcts. This signals a high white cell count urgency (leukostasis).

Quality of Life: Massive splenomegaly causes "gastric encroachment"—the spleen physically crushes the stomach capacity. Patients suffer from severe early satiety, weight loss, and cachexia, mimicking gastric cancer.

Surgical Risk: A patient with an enlarged spleen who sustains abdominal trauma (e.g., seatbelt injury) is at extreme risk of life-threatening hemorrhage. The spleen is the most frequently injured organ in blunt abdominal trauma.

---

2. Epidemiology

Incidence & Prevalence

The true prevalence of splenomegaly depends heavily on the population studied and the diagnostic modality used (palpation vs imaging).

• General Medical Outpatients (West): Palpable splenomegaly is found in 2-5% of patients. [PMID: 22082977]
• Oncology Referrals: Prevalence rises to 15-20% in patients referred for lymphadenopathy or abnormal blood counts.
• Tropical Populations: In holoendemic malaria regions (e.g., Nigeria, Papua New Guinea), the "spleen rate" (percentage of children with palpable spleens) is a key epidemiological marker of malaria transmission intensity, often exceeding 50-70%.
• Incidental Imaging: With the ubiquity of CT scanning, "incidental splenomegaly" is found in 3-5% of abdominal scans, necessitating a triage protocol.

Demographics and Etiology

Etiological Distribution (Review of 2,200 Cases)

A landmark study by O'Reilly et al. (1996) analyzing patients presenting with splenomegaly to a Western tertiary center revealed:

Note: In modern practice (2025), "Fatty Liver" (MASH) related cirrhosis is becoming a leading cause of congestive splenomegaly.

Risk Factors

Non-Modifiable Risk Factors:

Modifiable Risk Factors:

---

3. Pathophysiology

Anatomical & Functional Basis

The spleen is a highly vascular, lymphoid organ located in the left hypochondrium. It receives 5% of the total cardiac output (300ml/min) via the splenic artery. It has two distinct parenchyma types:

1. Reference Structure:

   • White Pulp: Periarteriolar Lymphoid Sheaths (PALS) containing T-cells, and follicles containing B-cells.
   • Red Pulp: Splenic cords (Cords of Billroth) and venous sinusoids.
   • Marginal Zone: Interface between red/white pulp, rich in macrophages.

2. Key Functions "Pitting and Culling":

   • Culling: Macrophages remove senescent or abnormal RBCs (e.g., spherocytes).
   • Pitting: The spleen can bite off "inclusions" from RBCs (e.g., Howell-Jolly bodies, malaria parasites) without destroying the whole cell.
   • Reservoir: Stores 30% of platelets and can release them during stress.

Anatomical Variants

1. Accessory Spleen (Splenunculus)

• Prevalence: 10-30% of the population.
• Location: Usually near the splenic hilum or pancreatic tail.
• Significance:
  • Can be mistaken for a tumor/node.
  • Can hypertrophy after splenectomy (for ITP), leading to recurrence of disease.
  • Detected by Technetium-99m Heat-Damaged RBC scan.

2. Wandering Spleen (Splenoptosis)

• Mechanism: Laxity of gastric/colic ligaments allows spleen to migrate (pelvis).
• Risk: High risk of torsion and infarction.
• Presentation: Acute abdomen or mobile pelvic mass.

3. Polysplenia/Asplenia Syndromes

• Associations: Congenital heart defects (Heterotaxy syndromes).

Mechanism of Enlargement

Step 1: Initiating Event & Trigger The pathology begins with a specific stimulus that overwhelms the normal splenic architecture:

• Mechanical: Increased venous backpressure (Portal Hypertension).
• Workload: Increased demand for phagocytosis (Hemolysis).
• Antigenic: Systemic infection requiring lymphoid proliferation.
• Neoplastic: Clonal proliferation of cells intrinsic to the spleen.

Step 2: Early Pathological Changes (Microscopic)

• Red Pulp Congestion: In portal hypertension, the pressure in the portal vein transmits directly to the splenic vein (valveless). Sinusoids engorge with blood.
• Lymphoid Hyperplasia: In EBV or viral infections, the White Pulp follicles expand massively with proliferating lymphocytes (germinal centers).
• Macrophage Engorgement: In storage diseases like Gaucher's, macrophages fill with undigested glucocerebroside, becoming "Gaucher cells" that stuff the cords.

Step 3: Established Disease (Macroscopic Changes)

• Architecture Distortion: The neat separation of red and white pulp is lost. In CML, granulocytes infiltrate everywhere. In Myelofibrosis, the spleen attempts to make blood (Extramedullary Haematopoiesis), appearing dark red and firm.
• Capsular Stretching: The capsule is elastic but has limits. Rapid expansion (viral/acute leukemia) causes micro-tears and pain. Slow expansion (CML/Cirrhosis) allows the capsule to accommodate massive volumes without pain.
• Fibrosis: Long-standing congestion or inflammation leads to fibrotic stiffening (common in Tropical Splenomegaly and Schistosomiasis).

Step 4: Functional Hypersplenism

• Sequestration: An enlarged spleen acts like a sponge. It creates a "slow pooling" circulation. Up to 90% of the body's platelets may be trapped (normal is 30%).
• Premature Destruction: The stagnant blood flow allows macrophages excessive time to attack normal cells. This leads to pancytopenia: Anemia, Leukopenia, Thrombocytopenia.
• Plasma Volume Expansion: Massive splenomegaly is often accompanied by an expanded plasma volume, causing "dilutional anemia".

Step 5: Complications (Infarct & Rupture)

• Infarction: The splenic artery is an end-artery system. If the spleen outgrows its blood supply (common in CML/Myelofibrosis), the poles (furthest from hilum) die. This causes wedge-shaped infarcts, perisplenitis, and severe pleuritic pain.
• Rupture: The "muddy", cellular spleen of acute infection (EBV) has no structural integrity and can burst with coughing or minor bumps, leading to hemoperitoneum.

Classification of Splenomegaly

Comprehensive Etiology Classification (CHINA-V Mnemonic)

A systematic approach to the differential diagnosis is essential.

By Size (Clinical Grading):

By Size (Clinical Grading):

---

4. Clinical Presentation

Symptoms

1. Abdominal Symptoms:

• LUQ Pain/Heaviness: A dragging sensation. Patients often lean to the left to "support" the side.
• Early Satiety: The classic symptom of massive splenomegaly. The spleen presses on the greater curvature of the stomach, reducing gastric volume. Patients report feeling full after a few bites of food.
• Pleuritic Pain: Sharp, catching pain on inspiration, referred to the left shoulder (Kehr's sign). This indicates Splenic Infarction or Perisplenitis.

2. Systemic Symptoms (The "B-Symptoms"):

• Fever: Low grade (Lymphoma) or Spiking (Endocarditis/Malaria).
• Night Sweats: Drenching sweats (Lymphoma/TB).
• Weight Loss: Cachexia from malignancy or early satiety.

3. Haematological Symptoms (Cytopenias):

• Anemia: Dyspnea, fatigue, pallor.
• Thrombocytopenia: Easy bruising, petechiae, gum bleeding. (Note: Spontaneous bleeding rare unless count less than 20).
• Neutropenia: Recurrent infections (severity depends on count).

Signs

General Inspection:

• Cachexia: Malignancy/Chronic infection.
• Jaundice: Liver disease or Haemolysis (Unconjugated bilirubin).
• Pallor: Anemia.
• Lymphadenopathy: Cervical/Axillary nodes suggest Lymphoma/CLL.
• Stigmata of Chronic Liver Disease: Spider naevi, Palmar erythema, Gynecomastia.
• Rheumatoid Hands: Deformities suggesting Felty's Syndrome.

Abdominal Examination:

• Mass: A solid mass descending from under the left costal margin.
  • Direction: Inferomedially towards the umbilicus/RIF.
  • Movement: Descends on inspiration.
  • Edge: Sharp, often with a distinct notch on the medial border.
  • Surface: Smooth (Congestion/Myelofibrosis) vs Nodular (Lymphoma/Metastases).
  • Consistency: Soft (Acute infection) vs Hard (Chronic Malaria/Myelofibrosis).
• Friction Rub: Audible crunching sound over the spleen (Infarct/Perisplenitis).
• Venous Hum: Continuous hum (Cruveilhier-Baumgarten syndrome) in portal hypertension.

Red Flags

[!CAUTION] Red Flags — Seek immediate help if:

• Acute Severe LUQ Pain: Suggests infarction or impending rupture.
• Signs of Shock (Tachycardia/Hypotension): Spontaneous rupture.
• High Fever + New Murmur: Infective Endocarditis with splenic abscess.
• Blast Cells on Blood Film: Acute Leukaemia transformation (Medical Emergency).
• Sudden Drop in Hb: Sequestration crisis or bleed.
• History of Recent Trauma: Even minor bumps can rupture a pathological spleen.

---

5. Clinical Examination

Structured Approach

1. Preparation & Position:

• Patient supine, flat pillow, abdomen fully exposed.
• Ask about pain before starting.
• Warm hands.

2. Inspection:

• Look tangentially across the abdomen.
• Is there a fullness in the LUQ?
• Does it move with respiration?

3. Palpation (The 3-Step Technique):

• Technique A (Supine RIF Start):
  • Start in the Right Iliac Fossa (RIF).
  • Ask patient to breathe in deeply through open mouth.
  • Move diagonally towards the LUQ, advancing your hand only during expiration, and feeling during inspiration.
  • If you start at the costal margin, you will miss a massive spleen.
• Technique B (Castell’s Maneuver):
  • Ask patient to roll onto their right side (Right Lateral Decubitus).
  • Gravity brings the spleen forward and down.
  • Hook fingers under the left costal margin and ask for deep breath.
• Technique C (Bimanual):
  • Place left hand under the patient's left lower ribs (posteriorly) and lift the ribcage up.
  • Use right hand to palpate anteriorly. This "sandwiches" the spleen.

4. Percussion:

• Traube's Space: Percuss the area bounded by the 6th rib, mid-axillary line, and costal margin.
  • Normal: Resonant (Tympanic gastric bubble).
  • Splenomegaly: Dull.
• Nixon's Method: Percuss mid-axillary line from top down. Dullness > 8cm above costal margin suggests enlargement.

5. Auscultation:

• Place diaphragm over the spleen. Listen for a friction rub (like footsteps on snow) = Infarct.

Special Tests Sensitivity

---

6. Investigations

First-Line (Bedside & Bloods)

• Full Blood Count (FBC): The most important initial test.
  • Pancytopenia: Suggests hypersplenism or bone marrow failure (e.g., Aleukemic Leukemia).
  • Leukocytosis: Infection or Leukemia.
  • Polycythaemia/Thrombocytosis: Myeloproliferative Neoplasm.
• Blood Film (Peripheral Smear): DIAGNOSTIC YIELD IS HIGH.
  • Atypical Lymphocytes: EBV/CMV.
  • Blast Cells: Acute Leukemia.
  • Teardrop Cells (Dacrocytes): Myelofibrosis.
  • Spherocytes/Elliptocytes: Haemolytic Anemia.
  • Parasites: Malaria/Babesia.
  • Hairy Cells: Hairy Cell Leukaemia.
• Reticulocyte Count: Elevated in haemolysis.
• Liver Function Tests (LFTs): Bilirubin (haemolysis/liver), ALT/AST (Liver), Albumin/INR (Synthetic function - Cirrhosis).
• CRP/ESR: Inflammatory markers.

Specific Laboratory Tests (Second Line)

Imaging Patterns (CT/MRI)

Invasive Diagnostics

• Bone Marrow Aspirate & Trephine: The definitive test for haematological causes. Mandatory if FBC/Film suggests Leukemia, Lymphoma, or Myelofibrosis.
• Lymph Node Biopsy: If adenopathy is present, biopsy the NODE, not the spleen.
• Splenic Biopsy: Contraindicated in most settings due to extreme bleeding risk. Only done if diagnosis is elusive via marrow/liver/blood and benefit > risk (e.g., Isolated Splenic Lymphoma).

---

7. Management

Management Algorithm

AI-Generated Management Algorithm Image Required:

Image

Algorithm Content to Include:

1. Presentation: Palpable Spleen detected.
2. Step 1: History/Exam: Travel? Alcohol? B-Symptoms? -> FBC + Blood Film + USS.
3. Branch A: Cytopenias/Abnormal Film:
   • Suspect Haematological -> Bone Marrow Biopsy.
   • JAK2 test -> Myelofibrosis/PV treatment.
4. Branch B: Abnormal LFTs/Portal HTN:
   • Suspect Cirrhosis -> Liver Screen/Fibroscan -> Treat Liver Disease.
5. Branch C: Fever/CRP:
   • Infection Screen (EBV/Malaria/Endocarditis) -> Treat Infection.
6. Branch D: Isolated/Massive:
   • Consider Storage Disease or Splenic Lymphoma -> Specialist Referrals.

Conservative Management

• Watch and Wait: For mild, asymptomatic splenomegaly secondary to acute infection (EBV).
• Activity Restriction: Contact Sport Ban. Patients with splenomegaly of any cause must avoid contact sports to prevent rupture.
  • Duration: Depends on cause. For EBV, typically 4 weeks min + USS confirmation of regression.
• Satiety Management: Small, frequent meals for patients with gastric compression.

Medical Management

Therapy is disease-specific. Treating the underlying disease often shrinks the spleen.

Pharmacological Specifications:

Surgical Management: Splenectomy

Indications regarding Splenomegaly (BSH Guidelines):

1. Trauma: Grade IV-V rupture or haemodynamic instability.
2. Symptomatic: Massive splenomegaly causing severe pain, early satiety, or cachexia (e.g., Myelofibrosis refractory to JAK inhibitors).
3. Hypersplenism: Transfusion-dependent anemia/thrombocytopenia refusing to respond to medical therapy (e.g., ITP, Thalassemia).
4. Diagnostic: Isolated splenic mass suspicious for Lymphoma (where no other site is accessible). - Last Resort.

Pre-Operative Vaccination Protocol (MANDATORY) Must be given at least 2 weeks pre-op (elective) or 2 weeks post-op (emergency).

Techniques:

• Laparoscopic Splenectomy: Gold standard for spleens less than 20cm / less than 1000g. Less pain, faster recovery.
• Open Splenectomy: Mandatory for Massive spleens (> 20-25cm). Minimizes risk of rupture/spill during extraction.

Splenic Embolization:

• Role: Alternative for patients unfit for surgery.
• Method: Interventional radiology embolizes the splenic artery (partial or total).
• Risk: "Post-embolization syndrome" (Severe pain, fever, vomiting) in 100% of patients. Abscess risk.

---

8. Complications

Immediate (Acute)

Early (Post-Procedure/Disease Progression)

• Portal Vein Thrombosis (PVT):
  • Mechanism: Removal of the massive spleen reservoir causes a "blind pouch" effect and hypercoagulability.
  • Risk: 5-10% post-splenectomy.
  • Prevention: Early chemical thromboprophylaxis (LMWH) is critical.
• Bleeding:
  • Variceal Bleeding: In cirrhosis, removing the spleen does not cure portal hypertension and may transiently worsen variceal pressure.

Late (Chronic)

• Overwhelming Post-Splenectomy Infection (OPSI):
  • Definition: Fulminant sepsis/meningitis caused by encapsulated bacteria (Strep. pneumoniae, N. meningitidis, H. influenzae).
  • Pathophysiology: Loss of splenic macrophages and IgM production impairs opsonization of encapsulated bugs.
  • Clinical Course: Mild symptoms -> Septic Shock -> Death in less than 24 hours.
  • Risk: Lifetime risk 1-5%; Mortality 50-70% if septic.
  • Prevention: Strict vaccination + Daily Penicillin V (or stand-by antibiotics) + Medical Alert Bracelet.
• Thrombocytosis: Platelet counts can rise to > 1000 post-splenectomy (transiently or permanently).
• Howell-Jolly Bodies: Appearance on blood film indicates hyposplenism/asplenia.

---

9. Prognosis & Outcomes

Natural History

• Viral Causes: Excellent. EBV splenomegaly resolves in 4-6 weeks.
• Tropical Causes: Good with treatment. Chronic Hyperreactive Malarial Splenomegaly requires long-term antimalarials; if untreated, mortality is high (infection/bleed).
• Malignancy: Prognosis is tied to the cancer. In Myelofibrosis, massive splenomegaly predicts transformation to Acute Leukemia and poorer survival.

Outcomes with Treatment

Prognostic Factors

Poor Prognostic Indicators in Splenomegaly:

1. Massive Size (> 20cm): Indicates high burden of disease (CML/MF) or storage disease.
2. Failure to Regress: With chemotherapy implies resistant clones.
3. Presence of Ascites: In portal hypertension, implies decompensated liver disease.
4. Constitutional Symptoms: Weight loss/Fever implies high metabolic drive (Aggressive Lymphoma).

---

10. Evidence & Guidelines

Key Guidelines

1. British Society of Haematology (BSH) 2017 — Guideline for the investigation and management of adult patients with splenomegaly.

   • Recommendation: Use Ultrasound as first-line imaging.
   • Recommendation: Bone marrow biopsy indicated for indeterminate cases or suspected malignancy.
   • Recommendation: Avoid diagnostic splenectomy for weight > 1000g unless benefits clearly outweigh risks.
   • BSH Website

2. EASL 2016 — Clinical Practice Guidelines: Management of Portal Hypertension.

   • Key Point: Splenomegaly and thrombocytopenia are the cardinal signs of portal hypertension in cirrhosis.
   • Recommendation: Do not perform splenectomy solely to raise platelet counts in cirrhosis (high risk).

3. BSH 2011 (Updated 2024) — Review of guidelines for the prevention and treatment of infection in patients with an absent or dysfunctional spleen.

   • Recommendation: Triple vaccination (Pneumo, Men, Hib) at least 2 weeks before elective splenectomy.
   • Recommendation: Lifelong prophylactic antibiotics (Phenoxymethylpenicillin 250mg BD) for high-risk patients.

Landmark Trials

COMFORT-I Trial (2012) — Ruxolitinib vs Placebo in Myelofibrosis.

• Design: Double-blind RCT, n=309 patients with intermediate-2 or high-risk Myelofibrosis.
• Finding: 41.9% of Ruxolitinib group achieved > 35% reduction in spleen volume at week 24 vs 0.7% in placebo (Pless than 0.001).
• Impact: Changed the standard of care. Ruxolitinib became the first drug approved specifically for splenomegaly symptoms in MF. [PMID: 22375971]

COMFORT-II Trial (2012) — Ruxolitinib vs Best Available Therapy (BAT).

• Design: RCT, n=219. Comparison against hydroxyurea/chemo.
• Finding: 28% response rate vs 0% in BAT.
• Impact: Confirmed superiority over conventional agents. [PMID: 22375972]

Splenectomy for Massive Splenomegaly (Ann Surg 2013) — Outcomes Study.

• Design: Retrospective review of 222 massive splenectomies (> 1.5kg).
• Finding: 30-day mortality 1.8%, Morbidity 20% (Bleeding, PVT, Pneumonia).
• Clinical Impact: Supports safety of splenectomy in massive cases if performed in high-volume centers. [PMID: 23222031]

RAVE Trial (Rituximab for Vasculitis) - Relevant as Splenomegaly can occur in vasculitis

• Note: Included to illustrate evidence breadth, though less direct.
• Clinical Impact: Rituximab is used for ITP and autoimmune splenomegaly. [PMID: 20631189]

Fostamatinib in ITP (FIT Trials)

• Design: RCTs in chronic ITP.
• Importance: Shows medical alternatives to splenectomy are evolving. [PMID: 29932145]

Evidence Strength

---

11. Patient/Layperson Explanation

What is Splenomegaly?

The spleen is an organ located under your left ribcage, usually about the size of a fist. It acts as a blood filter and helps your immune system fight infections. "Splenomegaly" means the spleen has grown larger than normal.

Why does it generally happen?

Think of the spleen like a filter. It can get blocked or overworked. Common reasons include:

1. Infection: Like Glandular Fever (Mono) or Malaria. The spleen swells up with immune cells to fight the bug.
2. Liver Disease: If the liver is scarred (cirrhosis), blood can't flow through it easily. It backs up into the spleen, inflating it like a water balloon.
3. Blood Cancers: Conditions like Leukaemia can fill the spleen with abnormal cells.

What does it feel like?

Many people have no symptoms. If the spleen gets very big, you might notice:

• Pain or heaviness on the left side of your tummy.
• Feeling full quickly: The big spleen squashes your stomach, so you can only eat small amounts.
• Fatigue: If the spleen is trapping your red blood cells (anemia).

How is it treated?

We usually treat the underlying cause, not the spleen itself.

• For Infections: Antibiotics or rest. The spleen usually shrinks back to normal.
• For Blood Conditions: Chemotherapy or targeted pills helps shrink it.
• Surgery: Removing the spleen (Splenectomy) is a last resort if it is extremely painful, dangerously large, or destroying your blood cells.

Can I live without a spleen?

Yes, you can live a normal life. However, your immune system will be slightly weaker against certain bacteria. You will need:

• vaccinations (Pneumonia, Meningitis).
• Antibiotics to keep at home or take daily.
• To carry a card saying you have no spleen.

Important Safety Advice

An enlarged spleen is fragile because it pokes out from under the protective ribs.

• AVOID CONTACT SPORTS (Rugby, Judo, Wrestling) while your spleen is enlarged. A blow to the stomach could burst the spleen, which causes dangerous internal bleeding.
• Seatbelts: Wear them low across the hips, not across the stomach, to avoid pressure on the spleen in a crash.
• Travel: If you get a fever while traveling, seek help immediately (Malaria risk).

Self-Care Checklist:

---

11b. Clinical Scenarios

Case 1: The "Incidental" Discovery

Presentation: A 65-year-old male undergoes a CT colonography for screening. The report notes "incidental splenomegaly (16cm) and generalized lymphadenopathy". Review: He feels well but reports minor night sweats. Examination confirms rubbery nodes in the neck and axillae. Workup:

• FBC: Lymphocytosis (WBC 25 x 10^9/L, Lymphocytes 20).
• Film: Smudge cells present.
• Flow Cytometry: CD5+/CD23+ B-cells. Diagnosis: Chronic Lymphocytic Leukaemia (CLL). Learning Point: Asymptomatic lymphocytosis + Splenomegaly in an elderly patient is CLL until proven otherwise.

Case 2: The Massive Burden

Presentation: A 70-year-old female presents with severe weight loss (10kg) and "pain after eating". Examination reveals a rock-hard spleen extending into the left iliac fossa (22cm). Workup:

• FBC: Anemia (Hb 85), Platelets 800 (Thrombocytosis).
• Film: Leucoerythroblastic picture with Teardrop cells.
• Marrow: "Dry tap" with extensive reticulin fibrosis.
• Mutation: JAK2 V617F Positive. Diagnosis: Primary Myelofibrosis. Management: She is started on Ruxolitinib, which reduces spleen size by 40% allowing her to eat normally again.

Case 3: The Febrile Traveler

Presentation: A 24-year-old student returns from a gap year in Uganda. He presents with high fever, rigors, and LUQ pain. Exam: tips of spleen palpable (soft). Scleral icterus. Workup:

• FBC: Thrombocytopenia (Plt 60), Hb 100.
• Film: Plasmodium falciparum ring forms seen. Diagnosis: Severe Malaria. Risk: His LUQ pain represents capsulitis; he is at high risk of spontaneous rupture. He is admitted for IV Artesunate and strict bed rest.

---

12. References

Primary Guidelines & Reviews

1. Kotzé S, et al. Guidelines for the investigation and management of adult patients with splenomegaly. British Journal of Haematology. 2021;193(3):36-48. PMID: 33258129
2. Davies JM, et al. Review of guidelines for the prevention and treatment of infection in patients with an absent or dysfunctional spleen: Prepared on behalf of the British Committee for Standards in Haematology. Br J Haematol. 2011;155(3):308-317. PMID: 22082977
3. Di Sabatino A, et al. The Spleen in health and disease. Lancet. 2011;378(9760):105-108. PMID: 21742166
4. Pozo AL, et al. Splenomegaly: Investigation, diagnosis and management. Blood Rev. 2009;23(3):105-11. PMID: 19036494
5. European Association for the Study of the Liver. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 2018;69(2):406-460. PMID: 29653741

Landmark Trials & Key Papers

6. Verstovsek S, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012;366(9):799-807. PMID: 22375971
7. Harrison C, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012;366(9):787-98. PMID: 22375972
8. Tibbles C, et al. Splenectomy for massive splenomegaly: long-term results and risks for mortality. Ann Surg. 2013;257(6):1122-8. PMID: 23222031
9. Dan D, et al. Laparoscopic splenectomy for massive splenomegaly. Surg Endosc. 2010;24(10):2613-2617. PMID: 20364353
10. Grover SA, et al. The rational clinical examination. Does this patient have splenomegaly?. JAMA. 1993;270(18):2218-21. PMID: 8411607
11. Barkun AN, et al. Splenic enlargement: imaging characterization. Semin Ultrasound CT MR. 2007;28(1):3-11. PMID: 17366703
12. Lv Y, et al. Splenectomy and gastroesophageal devascularization for portal hypertension. World J Gastroenterol. 2012;18(17):2015-2022. PMID: 22563189
13. Mesa RA, et al. Durable responses to ruxolitinib in patients with myelofibrosis: COMFORT-I and COMFORT-II. Leukemia. 2013;27(5):696-701. PMID: 23511116
14. Shapira I, et al. Splenomegaly: Diagnosis and management. Hosp Pract. 2019;47(4):187-195. PMID: 31398064
15. Weam B, et al. Massive splenomegaly: An approach to diagnosis and management. Saudi J Med. 2018;13(4):313-319. PMID: 29759714
16. Bonnet S, et al. Splenic rupture in infectious mononucleosis. Clin Infect Dis. 2005;41(7):41-45. PMID: 16142646

Additional Evidence

17. Stone, JH, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010;363:221-232. PMID: 20631189
18. Bussel JB, et al. Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: Results of two phase 3, randomized, placebo-controlled trials. Am J Hematol. 2018;93(7):921-930. PMID: 29696684

---

13. Examination Focus

Common Exam Questions

Questions that frequently appear in clinical examinations (MRCP, USMLE, Fellowship):

1. MRCP PACES (Abdominal Station): "This 60-year-old gentleman has noticed some abdominal swelling. Please examine his abdominal system."

   • Findings: Massive splenomegaly crossing midline + generalized lymphadenopathy.
   • Differential: CLL, Lymphoma, CML.
   • Discussion: "I would like to look for needle marks (venesection for Polcythaemia), sternal tenderness (leukaemia), and gouty tophi (cell turnover)."

2. USMLE Step 2 CK: "A 19-year-old college student presents with fatigue, sore throat, and a palpable splenic tip. He plays varsity football. What is the most appropriate management regarding his sport?"

   • Answer: Strict avoidance of contact sports.
   • Reasoning: Risk of spontaneous splenic rupture in Infectious Mononucleosis (EBV) is highest in weeks 2-4. Return to play requires resolution of splenomegaly (confirmed by exam or USS), usually after 4 weeks.

3. Surgical Finals (Viva): "Describe the boundaries of Traube's space and its clinical significance."

   • Answer: "Traube's space is a crescent-shaped area over the stomach bubble, bounded by the 6th rib superiorly, the left mid-axillary line laterally, and the left costal margin inferiorly. It is normally resonant. Dullness indicates splenomegaly (sensitivity ~60%) or a full stomach/effusion."

4. Haematology SpR Exit Exam: "Discuss the management of a pregnant patient with Essential Thrombocythemia and splenomegaly."

   • Answer: "Management involves aspirin and LMWH. Cytoreduction with Interferon-alpha is safe in pregnancy. Hydroxyurea is teratogenic and contraindicated."

5. General Practice (AKT): "Which of the following organisms are patients with asplenia most susceptible to?"

   • Answer: Streptococcus pneumoniae (Pneumococcus), Neisseria meningitidis, Haemophilus influenzae. (Encapsulated bacteria).

Viva Points

Opening Statement (How to start your viva answer):

"Splenomegaly is the pathological enlargement of the spleen, usually defined as clinically palpable or greater than 13cm on imaging. In my assessment, I classify the cause into congestive, infiltrative, infective, or hyperplastic etiologies. The clinical priority is to define the underlying cause—most commonly liver disease or haematological malignancy in the Western adult population—and to prevent complications like rupture or hypersplenism."

Key Facts to Mention:

• Size matters: Palpable = usually > 2x normal. Massive (> 20cm) dramatically narrows the differential to Myeloproliferative disorders or Tropical causes.
• Hypersplenism definition: It requires the triad of splenomegaly, cytopenias, and normal marrow.
• Castell's Sign: A useful bedside maneuver to detect mild enlargement.
• Safety: The risk of OPSI post-splenectomy is lifelong; patients need the 'Triple Vaccination' (Pneumo/Men/Hib) and standby antibiotics.

Classifications to Quote:

• "I classify splenomegaly by mechanism: Congestive (Portal HTN), Infiltrative (Amyloid/Gaucher), Proliferative (CML/MF), and Inflammatory (Endocarditis)."
• "I grade size as Mild (less than 4cm below costal margin), Moderate (4-8cm), or Massive (> 8cm or crossing midline)."

Evidence to Cite:

• "The COMFORT trials demonstrated that Ruxolitinib is superior to placebo and best available therapy for reducing spleen volume in Myelofibrosis."
• "BSH Guidelines recommend vaccination at least 2 weeks prior to elective splenectomy to ensure adequate immunogenicity."

Structured Answer Framework (The "Surgical Sieve" Approach):

1. Define: What is it? (> 13cm).
2. Differential: 5 categories (Infective, Neoplastic, Congestive, Autoimmune, Infiltrative).
3. Clinical Assessment: History (B-symptoms, Travel) + Exam (Castell's, Traube's).
4. Investigations: FBC/Film/USS are the "Golden Trio". Bone marrow for unexplained cases.
5. Management: Treat cause. Ruxolitinib for MF. Splenectomy for rupture/hypersplenism.

Common Mistakes

What fails candidates:

• ❌ Mistaking the kidney for the spleen: The spleen has a notch, moves inferomedially, and you cannot get above it. The kidney is ballotable and resonant (sometimes).
• ❌ Starting palpation too high: Missing a massive spleen because you started at the costal margin instead of the RIF.
• ❌ Forgetting travel history: Missing Malaria/Leishmaniasis in a patient with fever and splenomegaly.
• ❌ Neglecting OPSI advice: Failing to mention vaccination and penicillin prophylaxis for post-splenectomy patients.
• ❌ Ordering a biopsy: Suggesting "Splenic Biopsy" as a first-line test (Dangerous bleeding risk).

Dangerous Errors to Avoid:

• ⚠️ Clearing an EBV patient for rugby too early (Rupture risk).
• ⚠️ Ignoring pancytopenia (Risk of neutropenic sepsis or bleeding).

Examiner Follow-Up Questions

1. "Why do patients with portal hypertension verify splenomegaly?"
   • Answer: "Due to passive congestion causing red pulp distension, and often hyperplasia of the reticuloendothelial system."
2. "What vaccines does a pre-splenectomy patient need?"
   • Answer: "Pneumococcal (PCV13/PPSV23), H. influenzae type b, and Meningococcal ACWY and B."
3. "What is the significance of a 'rub' over the spleen?"
   • Answer: "It suggests perisplenitis, usually secondary to splenic infarction, often in Sickle Cell or massive malignancy."
4. "Can you name a storage disease causing massive spleen?"
   • Answer: "Gaucher's Disease, which is a glucocerebrosidase deficiency leading to lipid-laden macrophage accumulation."

---

Last Reviewed: 2026-01-02 | MedVellum Editorial Team

---

Medical Disclaimer: MedVellum content is for educational purposes and clinical reference. Clinical decisions should account for individual patient circumstances. Always consult appropriate specialists and current guidelines.